


ASTRAZENECA PLC

Interim Financial Statements

30 JUNE 2001



Registered number : 2723534

ASTRAZENECA PLC

PROFIT AND LOSS ACCOUNT

for the six months to 30 June 2001

	Notes	Six months to 30 June 2001 \$m	Year ended 31 Dec 2000 \$m
Turnover		-	-
Operating income/(costs)		2	(10)
Operating profit/(loss)		2	(10)
Income from shares in subsidiary undertakings		2,304	2,438
Profit on ordinary activities before merger costs and interest		2,306	2,428
Zeneca Agrochemicals demerger costs		-	(30)
Capital contribution to Syngenta AG		-	(212)
Net interest and exchange gains/losses	2	22	(249)
Profit on ordinary activities before taxation		2,328	1,937
Taxation		(7)	42
Net profit for the period		2,321	1,979
Dividends to Shareholders	3	(405)	(3,353)
Profit retained for the period		1,916	(1,374)

STATEMENT OF TOTAL RECOGNISED GAINS AND LOSSES

for the six months to 30 June 2001

	Six months to 30 June 2001 \$m	Year ended 31 Dec 2000 \$m
Net profit for the period	1,916	1,979
Exchange (loss)/gain on receivable arising on transfer of investment in Astra AB	-	(3,478)
Revaluation of investments	-	2,116
Total recognised gains and losses for the period	1,916	617

ASTRAZENECA PLC

BALANCE SHEET

as at 30 June 2001

	Notes	30 June 2001 \$m	31 Dec 2000 \$m
Fixed Assets			
Fixed asset investments	4	6,736	6,736
		6,736	6,736
Current assets			
Debtors		29,113	27,944
		29,113	27,944
Total assets		35,849	34,680
Creditors due within one year			
Short-term borrowings		(3)	-
Other Creditors		(420)	(889)
		(423)	(889)
Net current assets		28,690	27,055
Total assets less current liabilities		35,426	33,791
Creditors due after more than one year			
Loans		(590)	(590)
		(590)	(590)
Net Assets		34,836	33,201
Capital and reserves			
Called-up share capital	5	440	442
Share premium account	6	298	235
Capital redemption reserve	6	5	3
Other reserves	6	2,239	2,239
Profit and loss account	6	31,854	30,282
Shareholders' funds - equity interests		34,836	33,201

The financial statements on pages 1 to 5 were approved by the Board of Directors on 30 January 2002 and were signed on its behalf by:



Tom McKillop
Director



Jonathan Symonds
Director

ASTRAZENECA PLC


NOTES RELATING TO THE FINANCIAL STATEMENTS

1 Basis of presentation of financial information

The AstraZeneca PLC accounts are presented in accordance with the accounting policies set out in the 2000 consolidated annual accounts.

2 Net interest and exchange gains/losses

	Six Months to 30 June 2001 \$m	Year ended 31 Dec 2000 \$m
Interest payable and similar charges		
Payable to subsidiary undertakings	(21)	(41)
External interest payable	-	(1)
Net exchange losses	-	(249)
	(21)	(291)
Interest receivable and similar income		
Receivable from subsidiary undertakings	21	42
Net exchange gains	22	-
	43	42
Net interest and exchange gains/losses	22	(249)



NOTES RELATING TO THE FINANCIAL STATEMENTS (continued)

3 Dividends to Shareholders

	Six months to 30 June 2001 cents per 25c Share	Year ended 31 Dec 2000 cents per 25c Share	Six Months to 30 June 2001 \$m	Year ended 31 Dec 2000 \$m
1 st interim	23c	23c	405	406
2 nd interim/final	-	47c	-	830
Dividend in specie	-	-	-	2,117
	23c	70c	405	3,353

4 Fixed Asset Investments

	Shares \$m	Loans \$m	Total \$m
Cost or valuation			
At beginning of period	6,145	591	6,736
Additions	-	-	-
Disposals	-	-	-
Cost or valuation and net book value at end of period	6,145	591	6,736

5 Called-up share capital

	Authorised 30 June 2001 \$m	Allotted, called-up and fully paid	
		30 June 2001 \$m	2000 \$m
Ordinary Shares (\$0.25 each)	440	440	442
Unissued Ordinary Share (\$0.25 each)	160	-	-
Redeemable Preference Shares (£50,000)	-	-	-
	600	440	442

The movements in share capital during the period can be summarised as follows:

	No of shares (million)	\$m
At beginning of period	1,766	442
Issue of shares	2	-
Repurchase of shares	(8)	(2)
At end of period	1,760	440

NOTES RELATING TO THE FINANCIAL STATEMENTS (continued)

6 Reserves

	Share Premium Account \$m	Capital Redemption Reserve \$m	Other Reserves \$m	Profit and Loss Account \$m	Total 2001 \$m	Total 2000 \$m
At beginning of period	235	3	2,239	30,282	32,759	35,813
Net gains for the period	-	-	-	2,321	2,321	617
Dividends	-	-	-	(405)	(405)	(3,353)
Share Repurchase	-	2	-	(344)	(342)	(351)
Share Premiums	63	-	-	-	63	33
At end of period	298	5	2,239	31,854	34,396	32,759

The balance on the profit and loss account at 30 June 2001 includes \$29,440m which is not available for distribution (31 December 2000 - \$29,440m) relating to the gain on the sale of Astra AB to a subsidiary in 1999. This gain, which represents an unrealised profit, will be realised as the underlying receivable is settled in cash. Included in other reserves is a special reserve of \$157m, arising on the redenomination of share capital in 1999. Of the remaining balance on other reserves, \$736m is distributable.

7 Reconciliation of Movements in Shareholders' Funds

	Six months to 30 June 2001 £m	Year ended 31 Dec 2000 \$m
Net profit for the period	2,321	1,979
Dividends	(405)	(3,353)
	1,916	(1,374)
Other recognised gains and losses	-	(1,362)
Issues of AstraZeneca Ordinary Shares	63	33
Repurchase of AstraZeneca Ordinary Shares	(344)	(353)
Net reduction/addition to shareholders' funds	1,635	(3,056)
Shareholders' funds at beginning of period	33,201	36,257
Shareholders' funds at end of period	34,836	33,201

On 27th June 2001, 650,000 shares were repurchased for cancellation on 2nd July. The cost of repurchase, \$30m, is not reflected in the above statements.